四環醫藥(00460.HK)公佈年度業績 醫美業務銷售收益大幅上升約65.4%
格隆匯3月17日丨四環醫藥(00460.HK)發佈公吿,截至2024年12月31日止年度,集團取得總收益約為人民幣1,901.1百萬元,同比上升約2.2%。來自醫美業務的銷售收益約為人民幣744.2百萬元,同比上升約65.4%,主要由於年內產品獲得市場的高度認可,從而推動醫美銷售收入大幅增長,疊加新產品銷售帶來的新增收入。
來自創新藥及其他藥品的收益約為人民幣57.6百萬元,同比上升約388.1%,主要由於軒竹生物科技股份有限公司自研的一類新藥安奈拉唑鈉於2023年下半年獲批上市並開始產生收入。以上銷售收益的變動趨勢符合中國國內當前的「創新驅動,騰籠換鳥」的行業政策趨勢。
年內集團經營虧損約為人民幣138.1百萬元(2023年:溢利人民幣161.7百萬元),其中包括以股份為基礎的付款約為人民幣418.0百萬元(2023年:人民幣89.1百萬元),同比增加約人民幣328.9百萬元,主要由於本年集團旗下創新藥子公司軒竹生物授出激勵股份所致,剔除這個影響,集團經營溢利與去年基本持平。
回顧轉型歷程,四環醫藥始終以市場需求為導向,前瞻性地將集團產品研發重心主動積極向創新性及服務性醫美產品進行轉型和調整。在醫美領域,集團通過自主研發和合作引進,逐步完善產品線,覆蓋輕醫美領域的所有基礎類別,並建立起強大的市場影響力。
在創新藥及生物藥領域,集團持續大規模投入研發及人力資源,聚焦消化、腫瘤、NASH、糖尿病四個重大疾病治療領域,同步推進多個創新藥及生物藥項目進入臨牀階段,近兩年更有近10個產品獲批上市。目前,集團已成功打造出具備60+輕醫美產品管線、40+創新藥及生物藥產品管線,並佈局了覆蓋全國的具備強大商業化能力的醫美和醫藥營銷網絡。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.